Breakthrough in Retinal Diseases: AI Detection & Treatment
This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.
Overview
Provider Statement
Jointly provided by Partners for Advancing Clinical Education and DKBmed, LLC.
Support Statement
This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.
Target Audience
Retina specialists, ophthalmologists
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss consequences of delayed treatment initiation for patients with nAMD.
- Discuss consequences of delayed treatment initiation for patients with DME.
- Describe efficacy and safety of newer anti-VEGF treatments for nAMD.
- Evaluate the benefits of newly available treatment anti-VEGF options for DR and DME.
Faculty
Rishi P. Singh, MD, FASRS
Vice President/Chief Medical Officer of Martin North and South Hospitals
Professor of Ophthalmology, Cleveland Clinic Lerner College of Medicine
Cleveland Clinic Martin Health
David Eichenbaum, MD, FASRS
Director of Research, Retina Vitreous Associates of Florida
Collaborative Associate Professor, Morsani College of Medicine, University of South Florida
Accreditation
Partners for Advancing Clinical Education (PACE)
Credit Designation
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE), DKBmed, and the Institute for Johns Hopkins Nursing. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
PACE designates this material enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
How to Participate in This Activity and Obtain CE Credit
There are no fees for participating and receiving CME contact hours credit for this activity. During the period of September 1, 2024 through August 31, 2025, participants must read the learning objectives and faculty disclosures and study the educational activity.
Disclosures
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Faculty reports the following relationship(s)
Rishi P. Singh, MD, FASRS
Vice President/Chief Medical Officer of Martin North and South Hospitals
Professor of Ophthalmology, Cleveland Clinic Lerner College of Medicine
Cleveland Clinic Martin Health
- Consultant, Advisor, Speaker: Alcon, Allergan/Abbvie, Apellis, Eyepoint, Iveric, Genentech/Roche, Regeneron Pharmaceuticals, Inc., Zeiss
David Eichenbaum, MD, FASRS
Director of Research, Retina Vitreous Associates of Florida
Collaborative Associate Professor, Morsani College of Medicine, University of South Florida
- Researcher: 4DMT, Aerie, Alexion, Allegenesis, Astellas, Aviceda, Bayer, EyePoint, Genimi, Genentech, Gyroscope, Ionis, Kodiak, Mylan, NGM, Novartis, Ocular Therapeutix, OcuTerra, Opthea, ONL, RegenxBio, Roche, Unit
- Consultant, Advisor, Speaker: Alimera, Allergan, Astellas, Bausch & Lomb, Bayer, Coherus/Sandoz, CorEvitas/Vestrum, Crinetics, EyePoint, Genentech, Kodiak, Novartis, Ocular Therapeutix, Ocuphire, Opthea, Outlook, Recens Medical, RegenxBio, ReVive, Roche, Samsara
- Equity Ownership: Boston Image Reading Center, US Retina
Unlabeled and Investigational Usage
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Copyright Statement
Copyright © DKBmed 2024. All rights reserved.
CE Questions?
Email info@dkbmed.com